"Quetiapine Fumarate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.
| Descriptor ID |
D000069348
|
| MeSH Number(s) |
D02.886.680.702.500.500 D03.633.300.276.500
|
| Concept/Terms |
Quetiapine Fumarate- Quetiapine Fumarate
- Fumarate, Quetiapine
- Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt)
ICI 204,636- ICI 204,636
- 204,636, ICI
- ICI-204636
- ICI204636
- ICI 204636
- 204636, ICI
Quetiapine- Quetiapine
- 2-(2-(4-dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
|
Below are MeSH descriptors whose meaning is more general than "Quetiapine Fumarate".
Below are MeSH descriptors whose meaning is more specific than "Quetiapine Fumarate".
This graph shows the total number of publications written about "Quetiapine Fumarate" by people in this website by year, and whether "Quetiapine Fumarate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quetiapine Fumarate" by people in Profiles.
-
Edelsohn GA. Editorial: Making Use of What We Know: Medical Decision-Making and Antipsychotics. J Am Acad Child Adolesc Psychiatry. 2019 11; 58(11):1051-1053.
-
Dusitanond P, Young WB. Neuroleptics and migraine. Cent Nerv Syst Agents Med Chem. 2009 Mar; 9(1):63-70.
-
Bustillo JR, Rowland LM, Jung R, Brooks WM, Qualls C, Hammond R, Hart B, Lauriello J. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology. 2008 Sep; 33(10):2456-66.
-
Pinninti NR, Mago R, Townsend J, Doghramji K. Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol. 2005 Dec; 25(6):617-8.
-
Chou KL, Hurtig HI, Jaggi JL, Baltuch GH, Pelchat RJ, Weintraub D. Electroconvulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators. Parkinsonism Relat Disord. 2005 Sep; 11(6):403-6.
-
Faustman WO, Ringo DL, Lauriello J, Lim KO, Pfefferbaum A. Effects of 'Seroquel' (quetiapine) on platelet serotonin-2 binding in schizophrenia. J Clin Psychopharmacol. 1996 Dec; 16(6):464-6.